Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Risk Factors For Developing Thyroid-Associated Ophthalmopathy Among Individuals with Graves’ Disease
source: JAMA Ophthalmology
year: 2015
authors: Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, Smith TJ, Douglas R
summary/abstract:Importance:
Thyroid-associated ophthalmopathy (TAO) is a common and debilitating manifestation of Graves disease (GD). Presently little is known about factors that may increase the risk of developing TAO among patients with GD.
Objective:
To identify risk factors associated with the development of TAO among individuals with newly diagnosed GD.
Design, Setting, and Participants:
In this longitudinal cohort study, all beneficiaries 18 years of age or older with newly diagnosed GD who were continuously enrolled in a large nationwide US managed care network and who visited an eye care professional 1 or more times from 2001 to 2009 were identified. International Classification of Diseases, Ninth Revision, Clinical Modification billing codes were used to identify those who developed manifestations of TAO. Multivariable Cox regression was used to determine the hazard of developing TAO among persons with newly diagnosed GD, with adjustment for sociodemographic factors, systemic medical conditions, thyrotropin levels, and medical and surgical interventions for management of hyperthyroidism.
Main Outcomes and Measures:
Manifestations of TAO measured by hazard ratios (HRs) with 95% CIs.
Results:
Of 8404 patients with GD who met the inclusion criteria, 740 (8.8%) developed TAO (mean follow-up, 374 days since initial GD diagnosis). After adjustment for potential confounders, surgical thyroidectomy, alone or in combination with medical therapy, was associated with a 74% decreased hazard for TAO (adjusted HR, 0.26 [95% CI, 0.12-0.51]) compared with radioactive iodine therapy alone. Statin use (for ≥60 days in the past year vs <60 days or nonuse) was associated with a 40% decreased hazard (adjusted HR, 0.60 [CI, 0.37-0.93]). No significant association was found for the use of nonstatin cholesterol-lowering medications or cyclooxygenase 2 inhibitors and the development of TAO.
Conclusions and Relevance:
If prospective studies can confirm our finding that a thyroidectomy and statin use are associated with substantially reduced hazards for TAO among patients with GD, preventive measures for this burdensome manifestation of GD may become a reality.
DOI: 10.1001/jamaophthalmol.2014.5103
read more full text
Related Content
-
How patients experience thyroid eye diseaseObjective: To determine the impact of t...
-
Ask a Doctor questions about Graves’ disease, thyroid eye disease, & Hashimoto’s thyroiditishttps://www.youtube.com/watch?v=RxElrnS6...
-
Total Thyroidectomy (Tx) Versus Thionamides (Antithyroid Drugs) in Patients With Moderate-to-Severe Graves’ Op...Background: Graves' disease (GD) is cha...
-
Drug Effects on the ThyroidThe list of medications, many commonly u...
-
Smoking and Eye DiseaseSmoking tobacco (cigarettes, cigars or p...
-
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye DiseaseContext: Thyroid eye disease (TED) is a...
-
Dr. Noel Rose – Introduction to Autoimmunityhttps://www.youtube.com/watch?v=bjTBZObW...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.